ClinicalTrials.gg
CompletedNCT01973790Updated Jun 28, 2017

Phase III, Long-term, Open-label Safety Study of Z-338

A Phase 3 interventional study of Z-338 in Dyspepsia, sponsored by Zeria Pharmaceutical. Completed at 36 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-06-28.

Sponsored by Zeria Pharmaceutical · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
207
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing Z 338 in Dyspepsia — 1 open to participants now, 1 under way, none of them phase 3. Z 338 · Dyspepsia.

Enrollment
7th of 11
207 · median 282
Started
2014
the only one that year
Phase 3
4 of 11
none open now
Registered
9th of 11
by date
Lead sponsor
7 of 11
Zeria Pharmaceutical

Among the 11 studies testing Z 338 in Dyspepsia, this one is the 7th largest by enrollment, is the only one that started in 2014, is one of 4 in phase 3, and was the 9th registered.

Dyspepsia

372 studies on the registry are indexed under Dyspepsia; 66 are open to participants now.

Browse Dyspepsia studies →

Open to participants now

1 of the 11 studies testing Z 338 in Dyspepsia is open now. Recruiting first, the newest first:

About Z 338

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 46 Dyspepsia studies recruiting now, 16 (35%) set no upper age limit and 23 (50%) stop at 75 or younger; 2 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing Z 338 in Dyspepsia, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the long-term safety of 100 mg Z-338 TID in European subjects with FD.

Read the detailed description

This is a Phase III, multicentre, single-arm, open-label study to evaluate the long-term safety of 100 mg Z-338 TID in subjects with FD.

The study comprises a screening period (up to 3 weeks), a run-in period (1 week) and an open-label treatment period (52 weeks). Including an additional 2-week follow-up period for assessment of AEs, the maximum duration of a subject's participation in the study will be 58 weeks.

03

Conditions studied

  • Dyspepsia

Browse trials for

Keywords

  • Z-338
  • Functional Dyspepsia
  • Postprandial Distress Syndrome
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects to provide written prior to any study procedures being performed
  • Subjects with a diagnosis of FD (postprandial distress syndrome) as defined by the Rome III Criteria
  • Subjects must present Postprandial Fullness or Early Satiation as the most bothersome symptom during the 6 months prior to informed consent.
  • Subjects must have a normal endoscopy result within the 6 months (3 months in case of subjects who are Helicobacter pylori positive) prior to informed consent or during the screening period.

Exclusion criteria

Exclusion Criteria:

  • Subjects on PPI(s) who are unable to discontinue PPI medication by the end of the screening period
  • Subjects taking drugs that affect gut motility, gut sensitivity and/or acid secretion who are unable to discontinue these drugs by the end of the screening period
  • Subjects who have received H. pylori eradication therapy during the 3 months prior to
  • Subjects with confirmed organic gastrointestinal disease
  • Subjects presenting with predominant complaints relieved by stool movements (irritable bowel syndrome)
  • Subjects presenting with predominant GORD symptoms
  • Subjects presenting with predominant complaints of chronic idiopathic nausea
  • Subjects with Type I or Type II diabetes
  • Subjects with (BMI) over 30 kg/m2
  • Subjects with any condition which, in the opinion of the Investigator, makes the subject unsuitable for entry into the study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
207 participants (actual)

Study arms

  • Experimental
    Z-338

    100mg TID

    Drug: Z-338

Interventions

  • DrugZ-338

    100mg TID

    Also known as: Acotiamide

06

What researchers measure

Primary outcomes

  1. General safety endpoints

    Adverse Events, 12-lead ECGs, Laboratory variables, Vital signs, Physical examination

    Time frame: up to 58 weeks

Secondary outcomes

  1. To explore the efficacy

    the use of LPDS to measure FD symptom severity and the effect of Z-338, the effect of Z-338 on the QoL in subjects with FD as measured by SF-36 survey and SF-NDI, the effect of Z-338 on work productivity in subjects with FD as measured by WPAI.

    Time frame: up to 52 weeks

07

Study locations

36 sites
  • Zeria Investigative site
    Leuven, Belgium
  • Zeria Investigative Site
    Plovdiv, Bulgaria
  • Zeria Investigative Sites
    Sofia, Bulgaria
  • Zeria Investigative site
    Varna, Bulgaria
  • Zeria Invetigative Site
    Liepaja, Latvia
  • Zeria Investivgative SIte
    Limbazi, Latvia
  • Zeria Investigative Sites
    Riga, Latvia
  • Zeria Investigative Site
    Alytus, Lithuania
  • Zeria Investigative Sites
    Kaunas, Lithuania
  • Zeria Investigative Site
    Klaipeda, Lithuania
  • Zeria Investigative Site
    Vilnius, Lithuania
  • Zeria Investigative Site
    Brasov, Romania
  • Zeria Investigative Sites
    Bucharest, Romania
  • Zeria Investigative Sites
    Cluj-Napoca, Romania
  • Zeria Investigative Site
    Sibiu, Romania
  • Zeria Investigative Sites
    Timisoara, Romania
  • Zeria Investigative Site
    Tirgu Mures, Romania
  • Zeria Investigative Site
    Kazan, Russian Federation
  • Zeria Investigative Site
    Ryazan, Russian Federation
  • Zeria Investigative Site
    Saratov, Russian Federation
  • Zeria Investigative Site
    Yaroslavl, Russian Federation
  • Zeria Investigative sites
    Bratislava, Slovakia
  • Zeria Investigative sites
    Kosice, Slovakia
  • Zeria Investigative Site
    Malacky, Slovakia
  • Zeria Investigative Site
    Martin, Slovakia
  • Zeria Investigative Site
    Nitra, Slovakia
  • Zeria Investigative Site
    Presov, Slovakia
  • Zeria Investigative Site
    Trnava, Slovakia
  • Zeria Investigative Site
    Gothenburg, Sweden
  • Zeria Investigative Sites
    Stockholm, Sweden
  • Zeria Investigative Site
    Dnipropetrovsk, Ukraine
  • Zeria Investigative Site
    Kyiv, Ukraine
  • Zeria Investigative Site
    Vinnytsya, Ukraine
  • Zeria Investigative site
    Barnstaple, United Kingdom
  • Zeria Investigative site
    Bath, United Kingdom
  • Zeria Investigative Site
    Leamington Spa, United Kingdom
08

References and documents

Publications

  • Tack J, Pokrotnieks J, Urbonas G, Banciu C, Yakusevich V, Bunganic I, Tornblom H, Kleban Y, Eavis P, Tsuchikawa M, Miyagawa T. Long-term safety and efficacy of acotiamide in functional dyspepsia (postprandial distress syndrome)-results from the European phase 3 open-label safety trial. Neurogastroenterol Motil. 2018 Jun;30(6):e13284. doi: 10.1111/nmo.13284. Epub 2018 Jan 8. PubMed 29315999 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2014, a primary completion of Nov 2016 and a completion of Apr 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2013
First posted
Nov 1, 2013
Start
Mar 2014
Primary completionActual
Nov 2016
CompletionActual
Apr 2017
Last update
Jun 28, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 28, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01973790
Responsible party
Sponsor
First posted
Nov 1, 2013
Start date
Mar 2014
Primary completion
Nov 2016
Completion
Apr 2017
Last update
Jun 28, 2017

Study contacts

Jan Tack, MD, PhD
principal investigator · University of Leuven, University Hospital Gasthuisberg

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Z 338

Start the discussion